View Older Stories View More Recent Stories
-
Kalo Gold Samples 16,361 dU (~16.36 g/t Au est.) at New Kope Road North Occurrence as Wainikoro Heads Toward January Drilling
-
Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026
-
The Precision Peptide Company Advances Needle-Free GLP-1 Tirzepatide Patch into Formal U.S. Testing
-
Andean Precious Metals Reports Third Quarter 2026 Production and Sales Results
-
HyProMag USA Secures Power and Advances Project Readiness for Texas Recycling Magnet Manufacturing Hub
-
Lavras Gold Defines a District-Scale Gold-in-Soil Corridor at Lavras do Sul and Identifies Cerrito North as a New Exploration Target
-
Avenue Living Selects Elauwit to Deliver Managed WiFi Across 3 U.S. Communities in 3 States
-
Aurania Completes Drilling at Thormodsdalur Gold Project in Iceland
-
NTG Clarity Extends Framework Agreement with Saudi Customer by Four Years, up to $100M CAD In Additional Work
-
Uniserve Advances Strategic Transformation into Canadian Compute and Digital Infrastructure Platform; Adopts "COMP" Trading Symbol
-
BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity
-
Horizon Space Acquisition I Corp. Announces Definitive Business Combination Agreement with ArcheNova Biotech Corp.
-
Mizuho Downgrades Lantheus Holdings (LNTH) to Neutral
-
Jaguar Uranium releases first resource estimate for Argentina project
-
Wells Fargo beats profit estimates despite revenue miss
-
CoTec Holdings Corp. Notes EU Strategic Project Designation for HyproMag GmbH
-
H.C. Wainwright Reiterates Buy Rating on Envoy Medical (COCH)
-
H.C. Wainwright Reiterates Buy Rating on Palisade Bio Inc. (PALI)
-
H.C. Wainwright Reiterates Buy Rating on Zenas Biopharma (ZBIO)
-
Valor Gold Advances Optimization Program Targeting Updated Courageous Lake Pre-Feasibility Study in Q1 2028
-
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)
-
H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
-
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
-
Brightstar Lottery signs 5-year Pan Am licensing deal for global games
-
Mizuho Reiterates Outperform Rating on IonQ, Inc. (IONQ)
-
Rosenblatt Reiterates Buy Rating on Meta Platforms Inc. (META)
-
Jefferies Starts Electra (ETRA) at Buy
-
Mizuho Reiterates Outperform Rating on Diamondback Energy (FANG)
-
Enlight Renewable Engergy (ENLT) PT Lowered to $41 at Mizuho
-
Energy Transfer (ET) PT Raised to $26 at Mizuho
-
JPMorgan (JPM) Misses Q3 EPS by 18c, Misses on Revenue
-
Comprehensive Healthcare Systems to acquire TPA America's Choice Healthplans
-
ServiceNow (NOW) PT Raised to $165 at Oppenheimer
-
Emera (EMA) Declares $0.74 Quarterly Dividend; 6.5% Yield
-
Wells Fargo (WFC) Tops Q3 EPS by 3c; misses on revenue, NII
-
Bluejay Diagnostics meets Toray manufacturing deadline early
-
NEXT10 completes phase one mining investment, targets 120 oz gold monthly
-
U.S. Army selects Viavi T/Rx system for drone test ranges
-
Integra Resources advances DeLamar project, taps GenCap for financing
-
Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness
-
Heliostar Submits Environmental Permit Applications for Ana Paula
-
Hannan Restarts Drilling at Stavaträsk Gold Project, Sweden 1,000 m Program to Follow Up IP Chargeability Targets and High-Grade Gold from Maiden Drilling
-
Comprehensive Healthcare Systems to Acquire Third Party Administrator (TPA) America's Choice Healthplans, Moving from Benefits Software to Benefits Outcomes
-
Americas Gold and Silver Publishes Inaugural Corporate Sustainability Report and Establishes GHG Baseline
-
Mining Americas Reports Third Quarter 2026 Gold Production and Provides Notice of Third Quarter Results and Conference Call
-
FB Financial Corporation (FBK) Reports In-Line Q3 EPS
-
BofA Securities Downgrades Pershing Square Inc (PS) to Underperform
-
Darzalex Q3 2026 net sales reach $4.24 billion, reports Genmab
-
FB Financial Corporation (FBK) Reports In-Line Q3 EPS
-
Johnson & Johnson (JNJ) Tops Q3 EPS by 6c; adjusts forecast
